Abstract:Background: The National Drug Price Negotiation (NDPN) policy has entered a normalisation stage, aiming to alleviate, to some extent, the disease-related and economic burdens experienced by cancer patients. This study analysed the use and subsequent burden of anticancer medicines among cancer patients in a first-tier city in northeast China. Methods: We assessed the usage of 64 negotiated anticancer medicines using the data on the actual drug deployment situation, the frequency of medical insurance claims and actual medication costs. The affordability of these medicines was measured using the catastrophic health expenditure (CHE) incidence and intensity of occurrence. Finally, we used the defined daily doses (DDDs) and defined daily doses cost (DDDc) as indicators to evaluate the actual use of these medicines in the region. Results: During the study period, 63 of the 64 medicines were readily available. From the perspective of drug usage, the frequency of medical insurance claims for negotiated anticancer medicines and medication costs showed an increasing trend from 2018 to 2021. Cancer patients typically sought medical treatment at tertiary hospitals and purchased medicines at community pharmacies. The overall quantity and cost of medications for patients covered by the Urban Employee Basic Medical Insurance (UEBMI) were five times higher than those covered by the Urban and Rural Resident Medical Insurance (URRMI). The frequency of medical insurance claims and medication costs were highest for lung and breast cancer patients. Furthermore, from 2018 to 2021, CHE incidence showed a decreasing trend (2.85-1.60%) under urban patients' payment capability level, but an increasing trend (11.94%-18.42) under rural patients' payment capability level. The average occurrence intensities for urban (0.55-1.26 times) and rural (1.27-1.74 times) patients showed an increasing trend. From the perspective of drug utilisation, the overall DDD of negotiated anticancer medicines showed an increasing trend, while the DDDc exhibited a decreasing trend. Conclusion: This study demonstrates that access to drugs for urban cancer patients has improved. However, patients' medical behaviours are affected by some factors such as hospital level and type of medical insurance. In the future, the Chinese Department of Health Insurance Management should further improve its work in promoting the fairness of medical resource distribution and strengthen its supervision of the nation's health insurance funds.

Consumption Analysis of Hospital Antineoplastic Drugs in 6 Cities along Yangtse River Valley During 2004-2006

Antineoplastic Prescription among Patients with Colorectal Cancer in Eight Major Cities of China, 2015–2019: an Observational Retrospective Database Analysis

Analysis on the Trend of Drug Use in 22 Hospitals in Hangzhou Region During the Period from 2002 to 2004

Trends and Patterns of Five Antihypertensive Drug Classes Between 2007 and 2012 in China Using Hospital Prescription Data

Analysis on the Utilization of Oral Antitumor Drugs

Status and Tendency of Anticancer Antibiotics from 2011 to 2013 in Nan-jing Sample Hospitals

Trends in Antineoplastic Drug Use, Cost and Prescribing Patterns among Patients with Lung Cancer in Nine Major Cities of China, 2016–2020: a Retrospective Observational Study Based on Inpatient and Outpatient Hospital Data

Analysis of the Utilization of Antineoplastic Drugs in 9 Cancer Hospitals of China in 2010

Cost and Amount of Consumption of Four Sorts of Drugs in Shanghai in the Years 1994～ 1999

Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.

The Situation of Drugs Used in the Hospitals of Shanghai District During the Period of 2000-2002

The Situation of Drugs Used in the Hospitals of Shanghai District During the Period of 1999-2001

Influence of Government Price Regulation and Deregulation on the Price of Antineoplastic Medications in China: a Controlled Interrupted Time Series Study.

Analysis of Application Frequency of Liver Protective Drugs Used in Beijing Cancer Hospital During 2003

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis

Analysis of the Utilization of Anti-osteoporosis Drugs in Beijing Jishuitan Hospital During 2008-2010

Tracing survey and analysis of usage of antibacterial agents for cancer patients

The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data

Changes of Drug Economic Burden of Patients in Shanghai after Implementation of National Essential Drug System

New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study

Analysis of Chinese Herbal Medicines Used in Our Hospital During the Period 2002～2005